ICER Questions Cost-Effectiveness of Novo Nordisk’s Diabetes Drug Rybelsus

Drug Industry Daily
A A
The Institute for Clinical and Economic Review (ICER) has questioned the cost-effectiveness of Novo Nordisk’s recently approved Type 2 diabetes treatment Rybelsus (oral semaglutide) compared to alternatives.

To View This Article:

Login

Subscribe To Drug Industry Daily